findmyKOL
Clinical trialNCT06453694RecruitingPhase 2Interventional

Efgartigimod for the Treatment of Acute Optic Neuritis

SponsorAnastasia Vishnevetsky, MD, MPHEnrollment20Optic Neuritis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are: * Is it feasible to use efgartigimod alfa for optic neuritis? * Is it feasible to run a larger trial testing efgartigimod alfa in optic neuritis? * Does efgartigimod alfa work better than placebo in improving how quickly and how much vision returns? Participants will: * have their vision and blood tested * be asked questions about their vision * will receive standard of care treatment with steroids regardless of whether they are receiving efgartigimod alfa or not * will have periodic visits over 6 months

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts, United States

    Marc Bouffard, MD
    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Anastasia Vishnevetsky, MD, MPHDenis T Balaban, MDMarc Bouffard, MDMichael Levy, MD, PhD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Aug 2025
Primary completion
31 Dec 2026
Completion
31 Jul 2027
Last update posted
10 Nov 2025
Registered enrollment
20
Registry id
NCT06453694

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 30 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.